Polycystic Ovary Syndrome (PCOS): Diagnosis & Treatment

The Most Common Endocrine Disorder in Women — Often Undiagnosed

Between 8% and 13% of women of reproductive age have polycystic ovary syndrome (PCOS), yet nearly 70% of affected women remain undiagnosed. The condition doesn't just affect reproductive health — it raises lifetime risk of type 2 diabetes threefold, increases cardiovascular disease risk, and is associated with elevated endometrial cancer risk due to chronic anovulation and unopposed estrogen exposure. PCOS is heterogeneous: no two patients present identically, which makes both diagnosis and treatment genuinely challenging.

The name itself is misleading. Ovarian "cysts" in PCOS are actually immature follicles arrested in development, not true cysts. Many women with PCOS do not have polycystic ovaries on ultrasound; conversely, polycystic-appearing ovaries are found in up to 20% of normal women.

Rotterdam Criteria: A Diagnosis Requiring Two of Three

The 2003 Rotterdam ESHRE/ASRM consensus established the most widely used diagnostic framework. PCOS is diagnosed when at least 2 of the following 3 criteria are present — after exclusion of other causes of androgen excess (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome):

• Oligo- or anovulation: fewer than 8 menstrual cycles per year, or cycles longer than 35 days
• Clinical or biochemical hyperandrogenism: hirsutism (Ferriman-Gallwey score ≥8), acne, androgenic alopecia, or elevated total/free testosterone/DHEAS
• Polycystic ovarian morphology: ≥12 follicles per ovary measuring 2–9 mm (updated to ≥20 follicles or ovarian volume >10 mL with modern ultrasound technology)

This creates four PCOS phenotypes, ranging from the "classic" presentation (all three criteria) to "non-hyperandrogenic PCOS" (criteria 1+3 only). Phenotype significantly affects metabolic risk and treatment priority.

Insulin Resistance: The Metabolic Driver

Approximately 70% of women with PCOS have insulin resistance, even those who are lean. The mechanism is partly unique to PCOS: a serine phosphorylation defect in the insulin signaling pathway impairs glucose uptake in muscle and adipose tissue while paradoxically preserving insulin's stimulatory effect on ovarian androgen synthesis. Higher insulin levels drive more androgen production from theca cells, worsening the hormonal milieu.

This insulin-androgen feedback loop is why lifestyle interventions producing even modest weight loss (5–10% body weight) restore ovulation in 30–55% of overweight PCOS patients. The mechanism isn't fat loss per se — it's insulin sensitization from caloric restriction and exercise-induced GLUT4 upregulation that breaks the cycle.

Inositol: Evidence Review

Myo-inositol and D-chiro-inositol are naturally occurring insulin sensitizers that function as second messengers in the insulin signaling pathway. In PCOS, urinary excretion of D-chiro-inositol is elevated — a possible compensatory mechanism that depletes tissue levels. The physiological ratio of myo-inositol to D-chiro-inositol in plasma is approximately 40:1.

Multiple randomized controlled trials and meta-analyses have evaluated inositol supplementation. A 2016 meta-analysis in Reproductive BioMedicine Online found myo-inositol 2–4 g/day significantly improved fasting glucose, fasting insulin, HOMA-IR, and testosterone levels compared to placebo. The ISGE (International Society of Gynecological Endocrinology) incorporated inositol into their 2020 PCOS guidelines as a first-line option for metabolic management.

• Typical dose: Myo-inositol 2 g twice daily, often combined with 50 mg D-chiro-inositol (40:1 ratio)
• Onset: metabolic markers improve within 3 months; menstrual regularity may take 6 months
• Safety: well-tolerated; mild GI effects at higher doses
• Comparison to metformin: comparable insulin-sensitizing effect in lean PCOS patients in several head-to-head trials

Metformin: Off-Label but Evidence-Supported

Metformin is FDA-approved for type 2 diabetes, not PCOS — but it has decades of off-label use supported by robust evidence. The drug activates AMP-activated protein kinase (AMPK), reducing hepatic glucose production and improving peripheral insulin sensitivity. In PCOS, metformin 1,500–2,000 mg/day restores ovulation in 30–55% of anovulatory patients, improves menstrual regularity, reduces androgen levels, and significantly lowers the risk of gestational diabetes.

The 2018 Cochrane review on metformin for PCOS found it improved ovulation rates (OR 3.88) and menstrual frequency versus placebo, though live birth rates in infertile women were not significantly better than clomifene citrate alone. Most international PCOS guidelines recommend metformin as second-line after lifestyle modification for metabolic features, and as adjunct therapy for ovulation induction.

Spironolactone, an aldosterone antagonist with anti-androgenic properties, is frequently used for the dermatological manifestations of PCOS — hirsutism and acne. At doses of 50–200 mg/day, it blocks androgen receptors in hair follicles and sebaceous glands. Clinical response for hirsutism requires 6 months minimum. It is teratogenic in male fetuses, requiring contraception in women of reproductive age.

This article is for informational purposes only. Consult a qualified healthcare professional.